Protocols
BCC-014-DFMO Phase II OPEN TO ACCRUAL
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
BCC-015 Phase II OPEN TO ACCRUAL *
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
COG-ADVL1921 Phase I OPEN TO ACCRUAL *
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
COG-AGCT1531 Phase III OPEN TO ACCRUAL
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
COG-AHEP1531 Phase II/III OPEN TO ACCRUAL
Pediatric Hepatic Malignancy International Therapeutic Trial
COG-ALLIANCE-AGCT1532-P3BEP Phase III ABANDONED *
Phase 3 Accelerated BEP Trial: A Randomised Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP Trial)
COG-ANBL1232 Phase III OPEN TO ACCRUAL
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma: A Groupwide Historically Controlled Phase III Study
COG-ANBL1531 Phase III OPEN TO ACCRUAL
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
COG-ANBL1821 Phase II OPEN TO ACCRUAL *
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
COG-APEC1621A Phase II OPEN TO ACCRUAL *
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
COG-APEC1621D Phase II OPEN TO ACCRUAL *
NCI-COG PEDIATRIC MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors
COG-APEC1621F Phase II OPEN TO ACCRUAL *
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
COG-APEC1621K Phase II OPEN TO ACCRUAL *
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
COG-AREN1721 Phase II OPEN TO ACCRUAL *
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
COG-AREN1921 Phase II OPEN TO ACCRUAL *
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
COG-ARST1921 Phase II OPEN TO ACCRUAL *
A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
SPOC-2012-001 Phase I OPEN TO ACCRUAL
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
SPRINGWORKS-MEK-NF-201 Phase II OPEN TO ACCRUAL
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Patients with Neurofibromatosis Type 1 (NF1) associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing and/or Causing Significant Morbidity